Skip to main content
SpringerLink
Log in

Beta blockers in heart failure

  • Clinical Reviews
  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

The rationale for beta blockade in heart failure is now well established. Heart failure mortality, which is predicted by neurohormonal activation, remains high despite modern treatment, including angiotensin-converting enzyme (ACE) inhibition, and additional neurohormonal blockade has further therapeutic potential. Previous clinical trial experience in heart failure, most of which has been in patients with idiopathic cardiomyopathy, indicates consistent improvement in ventricular function, although variable changes in symptoms and exercise performance. However, the major burden of heart failure occurs in patients with ischemic heart disease, and in this respect it is notable that beta blockade following myocardial infarction confers a significant mortality benefit in subgroups with heart failure. An overview of all currently available randomized clinical trials of beta blockade in heart failure, which includes more than 1600 patients, indicates a mortality risk reduction of approximately 20%, but with wide confidence intervals. A large scale trial with several thousand patients is required to confirm reliably a plausible 20% mortality reduction with beta blockade in heart failure. The dissociation of clinical and mortality effects demonstrated with other heart failure treatments indicates the necessity for an appropriately powered mortality study that could define a major improvement in heart failure therapy for the future. The response to beta blockade will vary according to heart failure severity. A cautious dosetitration approach is required in all cases. In severe heart failure, symptomatic improvement may result, but for the large group of patients with moderate and stable heart failure, the principal aim of treatment is improved longevity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nicklas JM, Benedict C, Johnstone ED, et al. Relationship between neurohormonal profile and one year mortality in patients with congestive heart failure and/or left ventricular dysfunction (abstr). Circulation 1991;84(Suppl II): II468.

    Google Scholar 

  2. Cohn JN, Simon A, Johnson G, and VHeFT Study Group. Relationship of plasma norepinephrine and plasma renin activity to mortality in heart failure: V-HeFT II (abstr). Circulation 1991;84(Suppl II):II310.

    Google Scholar 

  3. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978;41:233–243.

    Google Scholar 

  4. Francis GS, Goldsmith SR, Cohn JN. The relationship of exercise capacity to resting left ventricular performance and basal plasma norepinephrine levels in patients with congestive heart failure. Am Heart J 1982;104:725–731.

    Google Scholar 

  5. Cohn JN, Levine B, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819–823.

    Google Scholar 

  6. Francis GS, Benedict C, Johnstone DE, et al., for the SOLVD Investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724–1729.

    Google Scholar 

  7. Mancia G. Sympathetic activation in congestive heart failure. Eur Heart J 1990;11(Suppl A):3–11.

    Google Scholar 

  8. Olivari MT, Levine TB, Cohn JN. Abnormal neurohumoral response to nitroprusside infusion in congestive heart failure. J Am Coll Cardiol 1983;2:411–417.

    Google Scholar 

  9. Szakacs JE, Cannon A. Norepinephrine myocarditis. Am J Clin Pathol 1958;30:425–435.

    Google Scholar 

  10. Bigger JT. Why patients with congestive heart failure die: Arrhythmias and sudden cardiac death. Circulation 1987; 75(Suppl IV):IV28-IV35.

    Google Scholar 

  11. Chidsey CA, Braunwald E, Morrow AG. Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med 1965;39:442–451.

    Google Scholar 

  12. Daly PA, Sole MJ. Myocardial catecholamines and the pathophysiology of heart failure. Circulation 1990;82(Suppl I):I35-I43.

    Google Scholar 

  13. Sandoval AB, Gilbert EM, Rose CP, Bristow MR. Cardiac norepinephrine uptake and release is decreased in dilated cardiomyopathy (abstr). Circulation 1989;80(Suppl II): II393.

    Google Scholar 

  14. Petch MC, Nayler WG. Uptake of catecholamines by human cardiac muscle in vitro. Br Heart J 1979;41:336–339.

    Google Scholar 

  15. Sole MJ, Helke CJ, Jacobowitz DM. Increased dopamine in the failing hamster heart: Transvesicular transport of dopamine limits the rate of norepinephrine synthesis. Am J Cardiol 1982;49:1682–1690.

    Google Scholar 

  16. Pierpont GL, Francis GS, DeMaster EG, et al. Heterogenous myocardial catecholamine concentrations in patients with congestive heart failure. Am J Cardiol 1987;60:316–321.

    Google Scholar 

  17. Anderson FL, Port JD, Reid BB, Larrabee P, Hanson G, Bristow MR. Myocardial catecholamine and neuropeptide Y depletion in failing ventricles of patients with idiopathic dilated cardiomyopathy. Correlation with beta-adrenergic receptor down regulation. Circulation 1992;85:46–53.

    Google Scholar 

  18. Gilbert EM, Anderson JL, Deitchman D, et al. Long-term betablocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double-blind, randomised study of bucindolol versus placebo. Am J Med 1990;88:223–229.

    Google Scholar 

  19. Nemanich JW, Veith RC, Abrass IB, Stratton JR. Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischaemic or idiopathic cardiomyopathy. Am J Cardiol 1990;66:843–848.

    Google Scholar 

  20. Andersson B, Blomstrom-Lundqvist C, Hedner T, Waagstein F. Exercise haemodynamics and myocardial metabolism during long-term, beta-adrenergic blockade in severe heart failure. J Am Coll Cardiol 1991;18:1059–1066.

    Google Scholar 

  21. Mann DL, Cooper G. Propranolol prevents the myopathic effects of catecholamines in vitro: Implications for patients with congestive heart failure. Circulation 1988;78(Suppl II):II576.

    Google Scholar 

  22. Imperato-McGinley J, Gautier T, Ehlers K, Zullo T, Goldstein DS, Vaughan ED. Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a phaeochromocytoma. N Engl J Med 1987;316:793–797.

    Google Scholar 

  23. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: Progressive receptor down-regulation and subsensitivity to agonist response. Circulation 1986;74:1290–1302.

    Google Scholar 

  24. Bristow MR, Ginsburg R, Umans V, et al. Beta1- and beta2-adrenergic subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective beta1-receptor downregulation in heart failure. Circ Res 1986;59:297–309.

    Google Scholar 

  25. Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of beta-adrenergic receptor kinase and beta1-adrenergic receptors in the failing human heart. Circulation 1993;87:454–463.

    Google Scholar 

  26. Mahan LM, Koachman AM, Insel PA. Genetic analysis of beta-adrenergic receptor internalisation and down regulation. Proc Natl Acad Sci USA 1985;82:129–133.

    Google Scholar 

  27. Bristow MR, Hershberger RE, Port JD, Minobe W, Rasmussen R. Beta1- and beta2-adrenergic receptor-mediated adenylate cyclase stimulation in non-failing and failing human ventricular myocardium. Mol Pharmacol 1989;35: 295–303.

    Google Scholar 

  28. Hammond HK. Mechanisms for myocardial beta-adrenergic receptor desensitisation in heart failure. Circulation 1993; 87:652–654.

    Google Scholar 

  29. Lohse MJ, Benovic JL, Caron MG, Lefkowitz R. Multiple pathways of rapid beta2-adrenergic receptor desensitisation. J Biol Chem 1990;265:3202–3209.

    Google Scholar 

  30. Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ. Beta-arrestin: A protein that regulates beta-adrenergic receptor function. Science 1990;248:1547–1550.

    Google Scholar 

  31. Bristow MR, Hershberger RE, Port JD, et al. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990;82(Suppl I):I12-I25.

    Google Scholar 

  32. Murphee SS, Saffitz JE. Distribution of beta-adrenergic receptors in failing human ventricular myocardium. Implications for the mechanisms of down-regulation. Circulation 1989;79:1214–1225.

    Google Scholar 

  33. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved haemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989;79:483–490.

    Google Scholar 

  34. Waagstein F, Caidahl K, Wallentin I, Bergh C, Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy. Effects of short and long term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551–563.

    Google Scholar 

  35. Bristow MR, Gilbert EM, Olsen S, Larrabee P, Renlund DG, O'Connell JB. Long-term metoprolol therapy increases myocardial beta-adrenergic receptor density relative to placebo controls (abstr). J Am Coll Cardiol 1993;21(Suppl A): 101A.

  36. Bristow MR, Port JD, Hershberger RE, Gilbert EM, Feldman AM. The beta-adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure. Eur Heart J 1989;10(Suppl B):45–54.

    Google Scholar 

  37. Whyte K, Jones CR, Howie CA, Deighton N, Sumner DJ, Reid JL. Haemodynamic metabolic and lymphocyte beta2-adrenoceptor changes following chronic beta-adrenoceptor antagonism. Eur J Clin Pharmacol 1987;32:237–243.

    Google Scholar 

  38. Ikram H, Fitzpatrick D. Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet 1981;2: 490–493.

    Google Scholar 

  39. Currie PJ, Kelly MJ, McKenzie A, et al. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol 1984;3:203–209.

    Google Scholar 

  40. Anderson JL, Lutz JR, Gilbert EM, et al. A randomised trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985;55:471–475.

    Google Scholar 

  41. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy; A double-blind, randomised, placebo-controlled trial. Circulation 1985;72:536–546.

    Google Scholar 

  42. Leung W, Lau C, Wong C, Cheng C, Tai Y, Lim S. A double-blind cross-over trial of labetalol in patients with dilated cardiomyopathy (abstr). Circulation 1989;80(Suppl II):II118.

    Google Scholar 

  43. Pollock SG, Lystash J, Tedesco S, Craddock G, Smucker ML. Usefulness of bucindolol in congestive heart failure. Am J Cardiol 1990;66:603–607.

    Google Scholar 

  44. Bristow MR, O'Connell JB, Gilbert EM, et al., for the Bucindolol Investigators. Dose-response of chronic beta blocker treatment in heart failure from either idiopathic dilated or ischaemic cardiomyopathy. Circulation 1994;89: 1632–1642.

    Google Scholar 

  45. Woodley SL, Gilbert EM, Anderson JL, et al. Betablockade with bucindolol in heart failure caused by ischaemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84: 2426–2441.

    Google Scholar 

  46. Paolisso G, Gambardella A, Marrazzo G, et al. Metabolic and cardiovascular benefits deriving from β-adrenergic blockade in chronic congestive heart failure. Am Heart J 1992;123:1397–1404.

    Google Scholar 

  47. Waagstein F, Bristow MR, Swedberg K, et al., for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441–1446.

    Google Scholar 

  48. Krum H, Schwartz B, Sackner-Bernstein J, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe heart failure treated with converting-enzyme inhibitors (abstr). J Am Coll Cardiol 1993;21(Suppl A):114A.

    Google Scholar 

  49. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short-and long-term carvedilol administration on rest and exercise haemodynamic variable, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678–1687.

    Google Scholar 

  50. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves symptoms and left ventricular function in patients with congestive heart failure due to ischaemic or idiopathic delated cardiomyopathy (abstr). J Am Coll Cardiol 1993; 21(Suppl A):114A.

    Google Scholar 

  51. Fisher ML, Gottlieb SS, Plotrick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomised trial. J Am Coll Cardiol 1994; 23:943–950.

    Google Scholar 

  52. Wisenbaugh T, Katz I, Davis J, et al. Long-term (3 month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993; 21:1094–1100.

    Google Scholar 

  53. Eichhorn EJ, Heejch CM, Barnet JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischaemic dilated cardiomyopathy: A randomised, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310–1320.

    Google Scholar 

  54. CIBIS Investigators. A randomised trial of beta blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study. Circulation 1994;90:1765–1773.

    Google Scholar 

  55. Sano H, Kawabata N, Yonezawa K, Hiryama H, Sakuma I, Yasuda H. Metoprolol was more effective than captopril for dilated cardiomyopathy in Japanese patients. Circulation 1989;80(Suppl II):II118.

    Google Scholar 

  56. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta blocker, in patients with congestive heart failure due to ischaemic heart disease. Circulation 1995;92:212–218.

    Google Scholar 

  57. Bristow MR, Anderson FL, Port E, et al. Differences in beta-adrenergic neuroeffector mechanisms in ischaemic versus dilated cardiomyopathy. Circulation 1991;84:1024–1039.

    Google Scholar 

  58. Insel PA, Ransnas LA. G proteins and cardiovascular disease. Circulation 1988;78:1511–1513.

    Google Scholar 

  59. Feldman AM, Cates AE, Veazey WB, et al. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest 1988;82:189–197.

    Google Scholar 

  60. Neumann J, Schmitz W, Scholz H, von Meyerinck L, Doring V, Kalmar P. Increase in myocardial Gi-proteins in heart failure. Lancet 1988;2:936–937.

    Google Scholar 

  61. Lau C, Pun K, Leung W. Reduced stimulatory guanine nucleotide binding regulatory protein in idiopathic dilated cardiomyopathy. Am Heart J 1991;122:1787–1788.

    Google Scholar 

  62. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022–1036.

    Google Scholar 

  63. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979;1:1374–1377.

    Google Scholar 

  64. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Beneficial effects of long term betablockade in congestive cardiomyopathy. Br Heart J 1980;44:117–133.

    Google Scholar 

  65. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Adverse effects of beta blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J 1980;44:134–142.

    Google Scholar 

  66. Haber HL, Gimple LW, Simek CI, et al. Why do patients with congestive heart failure tolerate the initiation of betablocker therapy? (abstr). Circulation 1992;86(Suppl I):17.

    Google Scholar 

  67. Eichhorn EJ, Bedotto JB, Malloy CR, et al. Effect of betaadrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in haemodynamic, contractile and diastolic performance with bucindolol. Circulation 1990;82:473–483.

    Google Scholar 

  68. Sweeney ME, Fletcher BJ, Fletcher GF. Exercise testing and training with beta-adrenergic blockade: Role of drug washout period in “unmasking” a training effect. Am Heart J 1989;118:941–946.

    Google Scholar 

  69. Olsen SL, Yanowitz FG, Gilbert EM, et al. Betablocker related improvement in submaximal exercise tolerance in heart failure from idiopathic dilated cardiomyopathy (abstr). J Am Coll Cardiol 1992;19(Suppl A):146A.

    Google Scholar 

  70. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468–1475.

    Google Scholar 

  71. Bristow MR, Larrabee P, Muller-Beckmann, et al. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Investig 1992;70:S105-S113.

    Google Scholar 

  72. Yue T-L, Cheng H-Y, Lyske PG, McKenna PJ, et al. Carvedilol, a new vasodilator and beta-adrenergic antagonist, is an antioxidant and free radical scavenger. J Pharm Exp Ther 1992;263:92–98.

    Google Scholar 

  73. Yue T-L, McKenna PJ, Lysko PG, Ruffolo Jr RR, Feuerstein GZ. Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis 1992;97:209–216.

    Google Scholar 

  74. Lichstein E, Hager D, Gregory JJ, Fleiss JL, Rolnitzky LM, Bigger JT. for the Multicentre Diltiazem Postinfarction Research Group. Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure. J Am Coll Cardiol 1990;16:1327–1332.

    Google Scholar 

  75. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503–510.

    Google Scholar 

  76. The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BPPP); subgroup findings from randomised trials in post-infarction patients. Eur Heart J 1988;9:8–16.

    Google Scholar 

  77. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429–1435.

    Google Scholar 

  78. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293–302.

    Google Scholar 

  79. Furberg C. for the BHAT trial. Effect of propranolol in post-infarction patients with mechanical or electrical complications. Circulation 1984;69:761–765.

    Google Scholar 

  80. Ryden L, Ariniego R, Arnman K, et al. A double-blind trial metoprolol in acute myocardial infarction. Effects on ventricular arrhythmias. N Engl J Med 1983;308:614–618.

    Google Scholar 

  81. Lichstein E. Why do beta-receptor blockers decrease mortality after myocardial infarction? J Am Coll Cardiol 1985; 6:973–975.

    Google Scholar 

  82. Bigger JT, Coromilas J. How do beta-blockers protect after myocardial infarction? Ann Intern Med 1984;101:256–258.

    Google Scholar 

  83. Weksler BB, Gillick M, Pink J. Effects of propranolol on platelet function. Blood 1977;49:185–196.

    Google Scholar 

  84. Frishman WH, Lazar EJ. Reduction of mortality, sudden death and non-fatal reinfarction with beta-adrenergic blockers in survivors of acute myocardial infarction: A new hypothesis regarding the cardioprotective action of beta-adrenergic blockade. Am J Cardiol 1990;66:66G-70G.

    Google Scholar 

  85. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomised trials. Prog Cardiovasc Dis 1985;27:335–371.

    Google Scholar 

  86. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669–677.

    Google Scholar 

  87. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173–1158.

    Google Scholar 

  88. Anonymous. From cardiac to vascular protection: The next chapter [editorial]. Lancet 1992;340:1197–1198.

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Auckland School of Medicine, Auckland, New Zealand

    Norman Sharpe

Authors
  1. Norman Sharpe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharpe, N. Beta blockers in heart failure. Heart Failure Rev 1, 5–13 (1996). https://doi.org/10.1007/BF00128553

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00128553

Key Words

Search

Navigation